Pay in 4 interest-free payments of $375.00 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
The depth of color response and ifn-&alpha in the sample
and take the supernatant
Host Rabbit Antigen Vimentin Synonyms VIM Immunogen Synthetic Peptide Location Cytoplasm
Aurrand-Lions
ActRIIB Enzyme Activity Inhibitor Screening Kit Cell Proliferation Viability The depth of color responseProduct Specification Background STX 001, the leading program of Supercede, is a novel oral small molecule Activin Receptor Type II (ACTRII) kinase inhibitor currently in preclinical development for the treatment of obesity. In Phase II clinical studies, inhibiting the ACTRII signaling pathway has been proven to significantly reduce fat while stimulating an increase in lean body mass (muscle). For patients with obesity, achieving significant fat
US$ 34.53
US$ 22.64
US$ 61.83
US$ 114.25
US$ 148.02
US$ 4075.24
US$ 13.20
US$ 33.83